Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
Behavioural symptoms (change from baseline at 26 weeks measured using the NPI) · people with Alzheimer's disease
1 finding from 1 review
Acceptability · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of participants (change from baseline at 26 weeks) · people with Alzheimer's disease
1 finding from 1 review
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · pPostmenopausal women at higher risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.64 [0.33, 1.24]
Studies not reported
Very low
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.54 [0.22, 1.35]
Studies not reported
Very low
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.48 [0.03, 7.5]
Studies not reported
Low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Acute gout attacks · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with placebo (low certainty).
1 finding from 1 review
Pain · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Patient global assessment · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review